AstraZeneca and its global biologics R&D MedImmune have lifted the curtain on new Phase 3 data for their immunotherapy Imfinzi (durvalumab) in the treatment of unresectable Stage III non-small cell lung cancer (NSCLC) in patients whose disease had not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).
Ook interessant voor je
Reageer